Accreditation

General Information

● 2025 Desert Liver Conference
● March 7-8, 2025 Scottsdale, AZ
● Jointly provided by Postgraduate Institute for Medicine, Arizona Liver Health and elm Planning
● This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Educational Objectives

After completing this activity, the participant should be better able to:
● Identify the most recent guidelines for screening and diagnosing patients at risk of MASLD, formerly known as NAFLD.
● Develop an evidence-based treatment regimen for MASLD using latest clinical evidence.
● Discuss disease and treatment options to patients.
● Recognize and communicate risks and benefits of therapy.
● Recognize differential diagnosis for MASLD and MASH
● Characterize risk factors for PBC & be able to discuss different therapies for PBC.
● Identify diagnostic approaches for HCC and treatment options.
● Explain diagnostic criteria and diagnostic tools for minimal and overt HE.
● Define diagnostic and therapeutic strategies for HCC.
● Demonstrate understanding of the diagnostic approaches for PSC and the role of liver biopsy as well as what therapies are used for PSC and when.
● Demonstrate understanding of different currently available treatment options for different clinical manifestations of portal hypertension.
● Choose different interventions and treatment approaches to minimize inpatient health care utilization for patients with Steatotic Liver Disease (SLD).
● Recognize and understand the latest noninvasive imaging technologies (NITS’s) available.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. These relationships have been mitigated:

● Naim Alkhouri, MD, FAASLD, DABOM
Grant/Research Support from Grant/research support from 89Bio, Akero, AstraZeneca, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Corcept, DSM, Galectin, Genentech, Gilead, Hepagene, Healio, Hepion, Intercept, Inventiva, Ionis, Ipsen, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus.
Speakers Bureau with AbbVie, Alexion, Echosens, Eisai, Exelixis, Gilead, Intercept, Ipsen, Perspectum, Salix, and Theratechnologies.
Consultant with 89Bio, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept,
Madrigal, NorthSea, Novo Nordisk, Perspectum, Pfizer, Ipsen and Regeneron.

● Meena Bansal, MD
Grant funding from NIH, CDC/NIOSH, Pfizer, The Kinetix Group, Histoindex, and Siemens
Consultant/Advisory Board member with The Kinetix Group, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK, Boston Pharma, Merck, and Boeheringer-Ingelheim, and CurveBio

● Michael Betel
Grant/Research Support from Madrigal Pharmaceuticals, Novo Nordisk, Regeneron, Perspectum, Aegle Medical, Evidera, Medscape, Echosens, and Siemens-Healthineers
Speakers Bureau with Medscape Education, PPD, WebMD, and Obesity Canada.
Consultant/Advisory Board Member with Regeneron, World Wide Clinical Trials and Madrigal Pharmaceuticals, and Novo Nordisk

● Naga Chalasani, MD
Grant/Research Support from Exact Sciences and Boehringer-Ingelheim
Consultant/Advisory Board member with Madrigal, GSK, Pfizer, Biome Infusion, Ipsen, Zydus, Altimmune, Akero, and Eccogene
Non-Mutual funds Stock Ownership/Stock options with Equity in Heligenics

● Thomas Cotter, MD
Grant/Research Support from AASLD CTORA and NIAAA.
Consultant/Advisory Board member with Madrigal Pharmaceuticals

● Robert Gish, MD
Grant/Research Support from Gilead
Consultant and/or Advisory fees from Abacus, AbbVie, Albireo, Altimunne, Antios, Arrowhead, AstraZeneca, BlueJay Therapeutics, Brii Bio, Corcept, Dynavax, Effectus, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson, Lehrman Group, Gilead Sciences, GlaxoSmithKline, Helios, HepaTX, HepQuant, Intercept, Ipsen, Janssen, JBS Science, Kinnate Bio, Merck, Precision BioSciences, Pfizer, SeresTherapeutics, Topography Health, Tune Therapeutics, Venatorx, and Virion.
Advisory Consultant for Fibronostics, Fujifilm/Wako, Perspectum, Quest, and Sonic Incytes

● Anita Kohli, MD
Grant/Research support from 89Bio, Abbvie, Aligos, Altimmune, Amgen, Akero AstraZeneca, Genentech, Axcella, Bavarian Nordic, Boehringer Ingelheim, Bristol-Myers, Boston Pharmaceuticals, Corcept, Cymabay, Eli Lilly, Galectin, GSK, Gilead, Hepagene, Hepion, Intercept, Inventiva, lonis, Ipsen, Madrigal, Merck, NGM, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Regeneron, Salix, Terns, Takeda, Viking, VIR, and Zydus
Consultant/Advisory Board member: Madrigal, Gilead

● Jeffrey Lazarus, PhD, MIH, MA
Grant/Research Support from Gilead Sciences, Pfizer, AbbVie, Boehringer Ingelheim, Echosens, Madrigal, MSD, Novo Nordisk, and Roche Diagnostics
Speakers Bureau/Honoriaria for non-CME from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk, and Pfizer
Consultant/Advisory Board member with GSK, Echosens, Novovax, Novo Nordisk, Pfizer and Prosciento

● Richard Manch, MD
Grant/Research Support from Merck, 89BIO, Akero, and Salix
Speakers Bureau for Gilead, AbbVie, Intercept and Madrigal
Consultant/Advisory Board member for Ipsen

● Mazen Noureddin, MD, MHSC
Grant/Research Support from Allergan, Akero, BMS, Gilead, Galectin, Genfit, GSK, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, Shire, Takeda, Terns, Viking, and Zydus
Speakers Bureau/Honoraria from Madrigal
Consultant/Advisory Board member with Altimmune, Boehringer Ingelheim, Cytodyn, 89BIO, GSK, Madriga, Merck, Novo Nordisk, Prespecturm, Terns, and Takeda
Patent Holder/Royalties received from Rivus Pharma, Cytodyn, and ChronWell

● Jackie O’Leary, MD, MPH
Consulting fees from Cosmo, Genfit, Pharmain
Non-Mutual funds Stock Ownership/Stock Options with CVS

● Justin Reynolds, MD
Consultant/Advisory Board member with Madrigal, Novo Nordisk, Takeda, and Gilead
Speakers Bureau/Honoriaira for non-CME from Gilead and Madrigal

The PIM planners and others have nothing to disclose. The elm Planning, Arizona Liver Health planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, elm Planning and Arizona Liver Health. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 8.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 8.0 contact hours.

Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.